Foundation Medicine
Presence
Roche is one of the...
- Forbes Global 2000 (#76);
- Fortune 500 Europe (#38);
- Global Fortune 500 (#184);
- Russell 3000;
- Stoxx 600;
- Swiss market index.
Roche is a company listed under the stock ticker ROG (CH).
Roche has a direct presence in 23 countries.Roche has 39 subsidiaries including Cenexi, Chugai Pharmaceutical and Flatiron Health.
They are in:
- Pharmaceuticals70%
- Biotechnology25%
- Other5%
Acquisition, funding and merger involving Roche.
- Roche has announced the acquisition of Carmot Therapeutics (posted on December 7 2023).
Executives
View the org chart displaying its 11 main executives
Most searched biographies at Foundation Medicine
- Dan Malarek, Chief Executive Officer
- Michael Kling, Chief Technology Officer
- Lucas Dennis, Senior Vice President and Head of Research and Devel...
Popular executive movements at Foundation Medicine
- Dan Malarek has joined the company as Chief Executive Officer (posted on December 14 2023).
Create your alert
to follow the executive moves at Foundation Medicine.
Biotechnology
Roche has 2,281 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Foundation Medicine
- Foundation Medicine Announces Details of Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Lilly’s Retevmo® (selpercatinib) for Certain Patients with Solid Tumors
- Foundation Medicine Expands Partnership with Sequanta to Provide both Liquid and Tissue Genomic Profiling Services in China to Support Global Regulatory Filings
- Foundation Medicine Appoints Dan Malarek as Chief Executive Officer
- AnHeart Therapeutics and Foundation Medicine Announce Collaboration to Develop Tissue-Based and Liquid-Based Companion Diagnostics for Taletrectinib, a ROS1 Inhibitor
- U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) to Identify Patients with HR-Positive, HER2-Negative Advanced Breast Cancer
- U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Janssen’s AKEEGA™ (niraparib and abiraterone acetate Dual Action Tablet) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
- Foundation Medicine Announces Collaboration with Pierre Fabre Laboratories to Develop Companion Diagnostics in Non-Small Cell Lung Cancer
- Roche France, Foundation Medicine and the Institute Gustave Roussy announce unique partnership to provide in-house liquid biopsy genomic testing to cancer patients in France | Foundation Medicine
- U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Janssen’s AKEEGA™ (niraparib and abiraterone acetate Dual Action Tablet) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer | Fou
- View more press releases Close
Social media about Foundation Medicine
- Foundation Medicine on Wikipedia, Google News & Yahoo Finance
- Foundation Medicine on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Dan Malarek 
Call Foundation Medicine at +1 617...
